Evidence map›Paper›PMID 38497028›Full record

ArticleACS omega2024

Design, Synthesis, and

Iman Baramaki, Mehlika Dilek Altıntop, Rana Arslan, Feyza Alyu Altınok, Ahmet Özdemir, Ilhem Dallali, Ahmed Hasan, Nurcan Bektaş Türkmen

Open access · goldAbstract read
In one paragraph

Article in ACS omega, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
9.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 38 citations in OpenAlex.

  1. Article
  2. FeACS omega · 2026
    Article
  3. Facile Synthesis ofInternational journal of molecular sciences · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Chalcones as Emerging Antibacterial Scaffolds: A Mini Review.Mini reviews in medicinal chemistry · 2025
    Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Iman BaramakiLaboratory of Neurotherapeutics, Drug Research Program, Division of Pharmacology and Pharmacotherapy, Faculty of Pharmacy, University of Helsinki, 00014 Helsinki, Finland.ORCID https://orcid.org/0000-0002-5484-3818
Mehlika Dilek AltıntopDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University, 26470 Eskişehir, Turkey.ORCID https://orcid.org/0000-0002-8159-663X
Rana ArslanDepartment of Pharmacology, Faculty of Pharmacy, Anadolu University, 26470 Eskişehir, Turkey.
Feyza Alyu AltınokDepartment of Pharmacology, Faculty of Pharmacy, Anadolu University, 26470 Eskişehir, Turkey.
Ahmet ÖzdemirDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University, 26470 Eskişehir, Turkey.ORCID https://orcid.org/0000-0003-0280-5550
Ilhem DallaliDepartment of Pharmacology, Graduate School of Health Sciences, Anadolu University, 26470 Eskişehir, Turkey.
Ahmed HasanDepartment of Pharmacology, Graduate School of Health Sciences, Anadolu University, 26470 Eskişehir, Turkey.ORCID https://orcid.org/0000-0003-3771-6910
Nurcan Bektaş TürkmenDepartment of Pharmacology, Faculty of Pharmacy, Anadolu University, 26470 Eskişehir, Turkey.
Anadolu University · TRUniversity of Helsinki · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Indole-chalcone hybrids have burst into prominence as potent weapons in the battle against pain and inflammation due to their unique features, allowing these ligands to form pivotal interactions with biological targets. In this context, the base-catalyzed Claisen-Schmidt condensation of 3',4'-(methylenedioxy)acetophenone with heteroaromatic aldehydes carrying an indole scaffold yielded new chalcones (

Identifiers

PMID38497028
PMCPMC10938421
OpenAlexW4392243593

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.